A randomized crossover study to compare efavirenz and etravirine treatment

AIDS

Volumn 25, Issue 1, 2011, Pages 57-63

  Nguyen, Alain ^a   Calmy, Alexandra ^a   Delhumeau, Cécile ^a   Mercier, Isabelle K ^a   Cavassini, Matthias ^b   Fayet Mello, Aurélie ^b   Elzi, Luigia ^c   Genné, Daniel ^d   Rauch, Andri ^e   Bernasconi, Enos ^f   Hirschel, Bernard ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Infectious Diseases Unit   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f Hospital of Lugano   (Switzerland)

Author keywords

crossover; efavirenz; etravirine; neuropsychiatric side effects; preference

Indexed keywords

ALANINE AMINOTRANSFERASE; CD4 ANTIGEN; CHOLESTEROL; EFAVIRENZ; ETRAVIRINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DEPRESSION ANXIETY AND STRESS SCALE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EPWORTH SLEEP SCORE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SLEEP; SLEEP QUALITY SCORE; STANFORD SLEEPINESS SCALE; STRESS; SYMPTOM; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANXIETY DISORDERS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PYRIDAZINES; QUESTIONNAIRES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 78650306222     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833f9f63     Document Type: Article

References (30)

1. Staszewski S, Morales-Ramirez J, Tashima K, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341:1865-1873.
2. AIDSInfo. DHHS guidelines 2010. http://www.aidsinfo.nih.gov/Guidelines/ GuidelineDetail.aspx7GuidelinelD=7. [Accessed 7 April 2010] European AIDS Clinical Society. EACS recommendations 2010. http://www. europeanaidsclinicalsociety.org/guidelines.asp. [Accessed 7 April 2010].
3. Sustiva, Efavirenz, Bristol-Myers Squibb Company, Princeton, New Jersey, USA.
4. Blanch J, Martinez E, Rousaud A, Blanco JL, Garcia-Viejo MA, Peri JM, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr 2001; 27:336-343.
5. Adkins JC, Nobles S. Efavirenz Drugs. Drugs 1998; 56:1055-1066.
6. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143:714-721.
7. Fumaz CR, Tuldra A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, et al. Quality of life, emotional status and adherence in patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2002; 29:244-253.
8. Fumaz CR, Munoz-Moreno JA, Molto J, Negredo E, Ferrer MJ, Sirera G, et al. Long-term neuropsychiatric disorders on efavir-enz-based approaches: quality of life, psychologic issues and adherence. J Acquir Immune Defic Syndr 2005; 38:560-565.
9. Mehta U, MaartensG. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect Dis 2007; 7:733-738.
10. Mills A, Cahn P, Molina J, Nijs S, Vingerhoets J, Witek J. Etravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: pooled 96-week results [abstract MOPEB 036]. In: Poster presented at the 5th IAS Conference on HIV Pathogenesis; 19-22 July 2009; Cape Town, South Africa.
11. Campbell T, Grinsztejn B, Hartikainen J, Steven N, Witek J. Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials [abstract MOPEB038]. In: Poster presented at the 5th IAS Conference on HIV Pathogenesis; 19-22 July 2009; Cape Town, South Africa.
12. Trottier B, Mills A, Cahn P, Clotet B, Grinsztejn B, Towner W, et al. Durable efficacy and safety of etravirine in treatment-experienced, HI V-1-infected patients: pooled Week 96 results from the Phase III DUET-1 and DUET-2 trials [abstract PI48]. In: Poster presented at the 18th Annual Canadian Conference on HIV/AIDS Research (CAHR); 23-26 April 2009; Vancouver, Canada.
13. Dejesus E, Lalezari JP, Osiyemi OO, Ruane PJ, Ryan R, Kakuda TN, Witek J. Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naTve HIV-1 infected adults [abstract 0413]. In: Ninth International Congress on Drug Therapy in HIV Infection; 2008; Glasgow.
14. Boffito M, Jackson A, Lamorde M, et al. Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers. J Acquir Immune Defic Syndr 2009; 52:222-227.
15. Colombo S, Beguin A, Telenti A, Biollaz J, Buclin T, Rochat B, Decosterd LA. Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopina-vir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819:259-276.
16. Fayet A, Beguin A, de Tejada BM, Colombo S, Cavassini M, Gerber,et al. Determinationofunboundantiretroviral drug concentra- tionsbyamodifiedultrafiltration method reveals high variability in the free fraction. Ther Drug Monit 2008; 30:511-522.
17. Fayet A, Beguin A, Zanolari B, Cruchon S, Guignard N, Telenti A, et al. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:1057-1069.
18. Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales (DASS). Psychology Foundation Monograph. Sydney, Australia: University of New South Wales; 1993.
19. Brown TA, Chorpita BF, Korotitsch W, Barlow DH. Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. Behav Res Ther 1997; 1:79-89.
20. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14:540-545.
21. Hoddes E, Zarcone V, Smythe H, Phillips H, Dement WC. Quantification of sleepiness: a new approach. Psychophysiol-ogy 1973; 10:431-436.
22. Meijman TF, de Vries-Griever AH, de Vries G. The evaluation of the Groningen Sleep Quality Scale. Groningen: Heymans Bulletin (HB 88-13-EX); 1988.
23. Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. Value Health 2006; 9:320-333. (Pubitemid 44337785)
24. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001; 15:71-75. (Pubitemid 32055781)
25. Gutierrez F, Navarro A, Padilla S, Anton R, Masia M, Borras J, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005; 41:1648-1653.
26. Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J. The nucleoside backbone affects durability of efa-virenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals. J Acquir Immune Defic Syndr 2009; 51:140-146.
27. Swaden L, Sabin CA, Lampe FC, Youle MS, Johnson MA, Lip-man M. Efavirenz: what happens in the long term [abstract]? In: 9th Annual Conference of the British HIV Association; 24-26 April 2003; Manchester. BHIVA Conf 2003; 9:O9.
28. Scholler-Gyure M, Kakuda TN, Raoof A, De Smedt G, Hoetel-mans RM. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet 2009; 48:561-574.
29. Baede P, Piscitelli S, Graham N, Van't Klooster G. Drug interactions with TMC125, a potent next generation NNRTI [abstract A-1827]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2002; San Diego.
30. Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, et al., for the SWITCHMRK 1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396-407.